Tirzepatide: difference between revisions
Diff·revision 12 → 13·21:47, 16 Nov 2024
Difference between revision 12 and revision 13 of Tirzepatide. 6 lines changed; the page grew by 131 bytes.
| Revision 12 — 23:56, 29 Oct 2024 RetatrutideRuben (talk) copyedit 4,989 bytes +146 | Revision 13 — 21:47, 16 Nov 2024 OralSemaOswin (talk) fix the anchor on an internal link 5,120 bytes +131 | ||
|---|---|---|---|
| 49 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> | 49 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> |
| 50 | 50 | ||
| + | 51 | == See also == | |
| + | 52 | * [[Dual incretin agonist]] | |
| + | 53 | * [[Semaglutide]] | |
| + | 54 | * [[Retatrutide]] | |
| + | 55 | * [[Glucose-dependent insulinotropic polypeptide]] | |
| + | 56 | ||
| 51 | {{DEFAULTSORT:Tirzepatide}} | 57 | {{DEFAULTSORT:Tirzepatide}} |
| 52 | [[Category:Dual and triple agonists]] | 58 | [[Category:Dual and triple agonists]] |